share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manting Erik

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manting Erik

Transcode Therapeutics | 4:持股變動聲明-董事 Manting Erik
美股SEC公告 ·  06/18 16:22

Moomoo AI 已提取核心訊息

Erik Manting, a key figure at Transcode Therapeutics, Inc. [RNAZ], has engaged in a transaction involving the company's stock on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares Manting holds after the transaction remains unknown.
Erik Manting, a key figure at Transcode Therapeutics, Inc. [RNAZ], has engaged in a transaction involving the company's stock on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Consequently, the number of shares Manting holds after the transaction remains unknown.
2024年6月14日,Transcode Therapeutics(股票代號RNAZ)的關鍵人物Erik Manting參與了一筆與公司股票相關的交易。公告中未披露交易的具體細節,包括股份數量、股份性質、交易價格以及股份的總價值。交易的操作類型和狀態也未提供。因此,Manting在此交易後所持有的股份數量仍然未知。
2024年6月14日,Transcode Therapeutics(股票代號RNAZ)的關鍵人物Erik Manting參與了一筆與公司股票相關的交易。公告中未披露交易的具體細節,包括股份數量、股份性質、交易價格以及股份的總價值。交易的操作類型和狀態也未提供。因此,Manting在此交易後所持有的股份數量仍然未知。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息